0000000001098818

AUTHOR

Lucia Napoli

showing 6 related works from this author

Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma

2022

Background: Comprehensive and contemporary data pertaining large populations of patients with Primary Biliary Cholangitis (PBC) and hepatocellular carcinoma (HCC) are missing. Aim: To describe main characteristics and outcome of PBC patients with HCC diagnosed in the new millennium. Methods: Analysing the Italian Liver Cancer registry we identified 80 PBC patients with HCC diagnosed after the year 2000, and described their clinical characteristics, access to treatment and survival. Results: Median age of patients was 71 years and 50.0% were males. Cirrhosis was present in 86.3% of patients, being well-compensated in 58.0%. Median HCC diameter was smaller in patients under surveillance (2.6 …

MaleCarcinoma HepatocellularCholestatic liver disease; Outcome; Surveillance; Survival; TreatmentSurveillanceHepatologySurvivalPrognosiLiver Cirrhosis BiliaryRisk FactorSettore MED/12 - GASTROENTEROLOGIALiver NeoplasmsGastroenterologyCholestatic liver diseasePrognosisTreatmentRisk FactorsHumansFemaleTreatment.HumanAgedOutcome
researchProduct

The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study

2019

Background: The Italian Liver Cancer (ITA.LI.CA) prognostic system for patients with hepatocellular carcinoma (HCC) has recently been proposed and validated. We sought to explore the relationship among the ITA.LI.CA prognostic variables (ie tumour stage, functional score based on performance status and Child-Pugh score, and alpha-fetoprotein), treatment selection and survival outcome in HCC patients. Patients and Methods: We analysed 4,867 consecutive HCC patients undergoing six main treatment strategies (liver transplantation, LT; liver resection, LR; ablation, ABL; intra-arterial therapy, IAT; Sorafenib, SOR; and best supportive care, BSC) and enrolled during 2002-2015 in a multicenter It…

MaleOncologySorafenibmedicine.medical_specialtyPrognostic variableCarcinoma Hepatocellularmedicine.medical_treatmenttreatment selectionLiver transplantationhepatocellular carcinoma; prognostic variable; survival benefit; treatment selection;03 medical and health sciencesprognostic variable0302 clinical medicineInternal medicinemedicineHumanssurvival benefithepatocellular carcinoma; prognostic variable; survival benefit; treatment selectionAgedNeoplasm StagingRetrospective StudiesAged 80 and overHepatologyPerformance statusbusiness.industryLiver NeoplasmsHazard ratiohepatocellular carcinomaMiddle Agedmedicine.diseaseConfidence intervalItaly030220 oncology & carcinogenesisHepatocellular carcinomaFemale030211 gastroenterology & hepatologyLiver cancerbusinessmedicine.drug
researchProduct

Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interfer…

2016

none 48 no Background: In HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma (HCC), the time to HCC recurrence and the effects of sustained viral eradication (SVR) by interferon (IFN)-based or IFN-free regimens on HCC recurrence remain unclear. Aim: To perform an indirect comparison of time to recurrence (TTR) in patients with successfully treated early HCC and active HCV infection with those of patients with SVR by IFN-based and by IFN-free regimens. Methods: We evaluated 443 patients with HCV-related cirrhosis and Barcelona Clinic Liver Cancer Stage A/0 HCC who had a complete radiological response after curative resection or ablation. Active HCV infec…

Liver CirrhosisMaleCirrhosisDatabases FactualGastroenterologyHCV-infected cirrhotic patients; hepatocellular carcinoma; HCC; sustained viral eradication; SVR; interferon0302 clinical medicineRetrospective StudiePharmacology (medical)Prospective StudiesHCV-infected cirrhotic patientsHCCProspective cohort studyAged 80 and overLiver NeoplasmsGastroenterologyvirus diseasesHepatitis Chepatocellular carcinomainterferonMiddle AgedHepatitis CLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomaCatheter AblationInterferon030211 gastroenterology & hepatologyFemaleLiver cancerHumanAdultmedicine.medical_specialtyCarcinoma HepatocellularSVRLiver CirrhosiAntiviral AgentsFollow-Up Studie03 medical and health sciencesInternal medicinemedicineCarcinomaEarly Hepatocellular CarcinomaHumansAgedRetrospective StudiesAntiviral AgentHepatologybusiness.industrySettore MED/09 - MEDICINA INTERNARetrospective cohort studymedicine.diseasedigestive system diseasesSurgeryProspective Studiesustained viral eradicationInterferonsNeoplasm Recurrence LocalbusinessFollow-Up Studies
researchProduct

A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma

2017

Background & Aims: Determining risk for recurrence or survival after curative resection or ablation in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) is important for stratifying patients according to expected outcomes in future studies of adjuvant therapy in the era of direct-acting antivirals (DAAs). The aims of this meta-analysis were to estimate the recurrence and survival probabilities of HCV-related early HCC following complete response after potentially curative treatment and to identify predictors of recurrence and survival. Methods: Studies reporting time-dependent outcomes (HCC recurrence or death) after potentially curative treatment of HCV-relat…

Oncologymedicine.medical_specialtyCarcinoma HepatocellularrecurrenceHepatitis C virusmedicine.medical_treatmentmedicine.disease_causesurvivallaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicineAdjuvant therapyhepatocellular carcinoma; prognosis; recurrences; survivalHumansSurvival analysisHepatologyrecurrencesbusiness.industryLiver Neoplasmshepatocellular carcinomaHepatologymedicine.diseaseHepatitis Chepatocellular carcinoma; prognosis; recurrences; survival; Hepatology030220 oncology & carcinogenesisMeta-analysisHepatocellular carcinoma030211 gastroenterology & hepatologyprognosisNeoplasm Recurrence LocalbusinessAdjuvantprognosi
researchProduct

The evolutionary scenario of hepatocellular carcinoma in Italy: an update

2017

Background and aims Epidemiology of hepatocellular carcinoma is changing worldwide. This study aimed at evaluating the changing scenario of etiology, presentation, management and prognosis of hepatocellular carcinoma in Italy during the last 15 years. Methods Retrospective analysis of the ITA.LI.CA (Italian Liver Cancer) database including 5192 hepatocellular carcinoma patients managed in 24 centers from 2000 to 2014. Patients were divided into three groups according to the date of cancer diagnosis (2000-2004, 2005-2009 and 2010-2014). Results The main results were: 1) progressive patient aging; 2) progressive expansion of non-viral cases and, namely, of “metabolic” hepatocellular carcinoma…

OncologyMaleEtiologyDatabases FactualRadiofrequency ablationmedicine.medical_treatmentlaw.invention0302 clinical medicinelawEpidemiologyepidemiology; hepatocellular carcinoma; survival; treatment; HepatologyAged 80 and overSurveillancetreatmentLiver Neoplasmshepatocellular carcinomaMiddle AgedPrognosisItaly030220 oncology & carcinogenesisHepatocellular carcinomaCatheter Ablation030211 gastroenterology & hepatologyFemaleepidemiology; hepatocellular carcinoma; survival; treatmentepidemiologyalpha-FetoproteinsLiver cancerAdultmedicine.medical_specialtyCarcinoma Hepatocellularsurvival03 medical and health sciencesYoung AdultAge DistributionInternal medicinemedicineHumansSex DistributionAgedNeoplasm StagingRetrospective StudiesCirrhosiHepatologybusiness.industryCancer stageSettore MED/09 - MEDICINA INTERNACancermedicine.diseaseSurgeryepidemiology; hepatocellular carcinoma; survival; treatment; Adult; Age Distribution; Aged; Aged 80 and over; Carcinoma Hepatocellular; Catheter Ablation; Databases Factual; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Sex Distribution; Young Adult; alpha-FetoproteinsEtiologyPercutaneous ethanol injectionbusiness
researchProduct

Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma

2021

Background & Aims The Pre-TACE-Predict model was devised to assess prognosis of patients treated with trans-arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). However, before entering clinical practice, a model should demonstrate that it performs a useful role. Methods We performed an independent external validation of the Pre-TACE model in a cohort that differs in setting and time period from the one that generated the original model. Data from 826 patients treated with TACE for naïve HCC (2008-2018) were used to assess calibration and discrimination of the Pre-TACE-Predict model. Results The four risk-categories identified by the Pre-TACE-Predict model had gradient …

Liver CancerPre-TACE-Predict modelmedicine.medical_specialtybusiness.industryTrans-arterial chemoembolizationPharmaceutical Sciencehepatocellular carcinomamedicine.diseaseGastroenterologyComplementary and alternative medicineInternal medicineHepatocellular carcinomamedicinePharmacology (medical)Trans arterial chemoembolizationbusinessLiver Cancer International
researchProduct